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Abstract
The HER2-targeted therapy have profoundly changed the outcomes of women with 
HER2-positive breast cancers. Trastuzumab and pertuzumab, HER2-targeting monoclonal 
antibodies, lapatinib and Neratinib, small molecule inhibitors of HER2 and the epidermal 
growth factor receptor, and ado-trastuzumab emtansine, a HER2-positive directed anti-
body drug conjugate, are approved for the treatment of HER2-positive breast cancer.
Cardiac toxicity is a known adverse effects of trastuzumab, and other HER2-directed 
therapy. In most cases it manifests as mild and reversible left ventricle dysfunction. 
Nevertheless, symptomatic heart failure is not rare. The incidence and severity of cardiac 
dysfunction is greatest among women who received HER2-directed therapy in combina-
tion with anthracycline-based therapy. In addition, a borderline low normal left ventricle 
ejection fraction; prior treatment with antihypertensive medication; and older age are other 
risk factors for trastuzumab-related cardiac dysfunction. HER2 signaling plays an impor-
tant role in modulating myocardial response to treatment-related injury. Management of 
trastuzumab and the other HER2 targeted treatment-related cardiac dysfunction has two 
key components: withdrawal of HER2-directed therapy and treatment of underlying car-
diac dysfunction. A multidisciplinary approach is recommended for an optimal outcome. 
This chapter reviews cardiac toxicity of trastuzumab and other HER2-directed therapy 
including epidemiology and pathophysiology of cardiac dysfunction, cardiac monitoring, 
treatment and prevention.
Keywords: breast cancer, HER2-directed therapy, cardiac toxicity, trastuzumab, 
pertuzumab, lapatinib, T-DM1, Neratinib
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1. Introduction
Breast cancer is one of the most common cancers in women worldwide [1]. In 2012, nearly 
1.7 million women were diagnosed with breast cancer. This represents about 12% of all 
new cancer cases and 25% of all cancers in women [2]. Approximately 20–25% of all breast 
cancers overexpressed the human epidermal growth factor receptor-2 (HER2). This protein 
is a member of the HER family of transmembrane receptor tyrosine kinases and is located at 
the cell surface. HER2 is involved in cellular growth and differentiation, and its overexpres-
sion has been associated with adverse prognosis. Prior to the development of HER2-targeted 
therapy, women with HER2-positive breast cancer had poor outcomes. However, access to 
HER2-directed therapy including monoclonal antibodies, small molecule inhibitors, and 
antibody-drug conjugates in the management of early and advanced breast cancer has trans-
formed the natural history of HER2-positive breast cancer [3, 4]. HER2-targeted therapy alone 
or in combination with chemotherapy has been associated with improvements in response 
rate, disease control rates, and overall survival in HER2-positive metastatic breast cancer 
[3–5]. Combination of HER2-targeted agents including dual HER2 blockade and selected 
delivery of potent chemotherapeutic agent along with HER2 inhibition are new therapeutic 
approaches that in many women have transformed metastatic HER2-positive breast cancer 
into a chronic disease. More importantly, HER2 blockade in early-stage breast cancer has 
resulted in lower recurrence and mortality [3, 6].
As the outcomes of women with HER2-positive breast cancer have improved, increasingly 
attention has been directed toward minimizing both acute and chronic treatment-related 
toxicities. Cardiac toxicity is a known adverse effect of trastuzumab and other HER2-
directed therapy [7, 8]. In most cases, it manifests as mild and reversible left ventricle 
dysfunction. Nevertheless, overt heart failure is not unusual. Serial monitoring of cardiac 
function is recommended for women treated with HER2-directed therapy. In women with 
treatment-related cardiac dysfunction, trastuzumab and other HER2-directed therapy 
interruptions and treatment of cardiac dysfunction are recommended. This chapter pro-
vides a summary of efficacy of HER2-directed therapy in breast cancer and reviews the 
incidence, pathophysiology, risk factors, monitoring, and management and prevention of 
HER2-targeted treatment-related cardiac dysfunction.
2. Efficacy of HER2‐directed therapy
The current HER2-directed treatments for women with HER2-positive breast cancer include 
monoclonal antibodies, small molecule inhibitors, and antibody-drug conjugates (Table 1). 
Trastuzumab is the prototype humanized monoclonal antibody directed against the extracel-
lular domain of human epidermal growth factor receptor-2 [9]. It was first evaluated in women 
with HER2-positive metastatic breast cancer. The combination of trastuzumab and chemo-
therapy resulted in improvement in progression-free and overall survival compared with 
chemotherapy alone, in women with HER2-positive metastatic breast cancer [5]. A Cochrane 
review assessed efficacy and safety of trastuzumab in seven trials, involving 1497 women 
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with advanced breast cancer [10]. The combined hazard ratios (HRs) for overall survival and 
progression-free survival favored the trastuzumab-containing regimens (HR 0.82, 95% confi-
dence interval (CI) 0.71–0.94, p-value = 0.004; and HR 0.61, 95% CI 0.54–0.70, p-value < 0.00001, 
respectively).
Later trastuzumab was evaluated in women with early-stage breast cancer, in both adju-
vant and neoadjuvant settings, and demonstrated improvement in disease-free and overall 
survival. A Cochrane review evaluated efficacy and toxicity of trastuzumab in eight studies 
involving 11,991 women with early-stage breast cancer [11]. The combined HRs for overall 
survival and disease-free survival significantly favored the trastuzumab-containing regimens 
(HR 0.66; 95% CI 0.57–0.77, p-value < 0.00001; and HR 0.60; 95% CI 0.50–0.71, p-value < 0.00001, 
respectively). Based on results from five randomized adjuvant trials in women with node-
positive or high-risk node-negative breast cancer, 1 year of adjuvant trastuzumab has become 
the standard therapy for women with HER2-positive breast cancer [6, 12–14].
Lapatinib is a dual EGFR/HER2 reversible tyrosine kinase inhibitor that suppresses the down-
stream signaling involving MAPK/Erk1/2 and PI3K/Akt pathways by blocking both HER1 
and HER2 [15]. Lapatinib has demonstrated efficacy in HER2-positive advanced breast cancer 
[16]. In addition, it has been assessed in both adjuvant and neoadjuvant settings in women 
with early-stage breast cancer. However, overall the data suggest that lapatinib in early-stage 
breast cancer is inferior compared with trastuzumab [3, 17].
Class Comments
Monoclonal antibodies
Trastuzumab A humanized monoclonal antibody directed against the extracellular 
domain of the HER2 receptor that prevents ligand-independent HER2 
signaling. It has demonstrated efficacy in both early and advanced stage 
breast cancer
Pertuzumab A humanized monoclonal antibody that binds to the extracellular 
domain II of HER2 and inhibits ligand-dependent HER2-HER3 
dimerization. It has been evaluated in combination with trastuzumab in 
preoperative setting and advanced breast cancer
Antibody‐drug conjugates
Ado-trastuzumab emtansine An antibody-drug conjugate consisting of the cytotoxic agent DM1 
linked to trastuzumab. It has demonstrated efficacy in advanced breast 
cancer
Small molecules inhibitors
Lapatinib An oral dual EGFR/ErbB2 reversible tyrosine kinase inhibitor blocking 
both HER1 and HER2 that suppresses the downstream pathways. It has 
been evaluated in both early and advanced breast cancer.
Afatinib, Neratinib Irreversible tyrosine kinase inhibitor of EGFR/HER2/HER4
Table 1. List of current HER2-directed targeted drugs that are approved for the management of HER2-positive breast 
cancer.
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Pertuzumab is a humanized monoclonal antibody that binds to the extracellular domain II of 
HER2. It inhibits ligand-dependent HER2-HER3 dimerization and reduces signaling via intracel-
lular pathways such as PI3K/Akt [18]. Pertuzumab has limited antitumor clinical activity alone, 
but it is a very good synergistic drug when combined with trastuzumab and has demonstrated 
benefit in combination with trastuzumab in the treatment of both early (neoadjuvant setting) 
and advanced HER2-positive breast cancer [3, 19, 20]. In the neoadjuvant setting, the pooled 
pathological complete response rate in the dual anti-HER2 therapy group was 54.8% compared 
with 36% in the monotherapy group when used in combination with chemotherapy (relative 
risk [RR], 1.56; 95% CI 1.23–1.97; p-value < 0.001). In the metastatic setting, dual anti-HER2 
therapy demonstrated significant benefits in both progression-free survival (HR, 0.71; 95% CI 
0.62–0.81; p-value < 0.001) and overall survival (HR, 0.68; 95% CI 0.57–0.82; p-value < 0.001) [21].
Ado-trastuzumab emtansine (T-DM1) is an antibody-drug conjugate consisting of an anti-
microtubule cytotoxic agent DM1 linked to trastuzumab [22]. In women with HER2-positive 
advanced breast cancer, who were previously treated with trastuzumab and a taxane, it has 
shown significant improvement in progression-free and overall survival compared with lapa-
tinib plus capecitabine [23].
Neratinib is an irreversible binder of HER1, HER2, and HER3 receptors [22, 24] It has dem-
onstrated efficacy in HER2-positive breast cancer that progress on trastuzumab [3]. In addi-
tion, 1 year of neratinib following adjuvant chemotherapy and trastuzumab in women with 
HER2-positive breast cancer has been associated with modest improvement in disease-free 
survival [25].
In summary, over the past 15 years, HER2-directed therapy has revolutionized the man-
agement of HER2-positive breast cancer. In women with early-stage cancer, neoadjuvant 
and adjuvant HER2-directed therapies have substantially improved the disease-free and 
overall survival. Likewise, for many women, HER2-targeted therapy has transformed 
HER2-positive advanced breast cancer into a chronic disease. For example, median overall 
survival of women with HER2-positive advanced cancer has improved from 20.3 months 
reported by Slamon et al. in the first randomized trial using trastuzumab with chemo-
therapy to 48 months with the use of triple combination of pertuzumab, trastuzumab, and 
docetaxel [5, 26].
3. Cardiac safety of HER2‐directed therapy
3.1. Trastuzumab
Trastuzumab-related cardiac dysfunction incidence varies according to the underlying 
treated population and the definition of cardiac toxicity used in the clinical trials. In the piv-
otal clinical trial that evaluated trastuzumab in combination with chemotherapy (anthracy-
cline or taxane) in women with HER2-positive metastatic breast cancer, a high rate of cardiac 
dysfunction was noted, especially when trastuzumab was given in combination with an 
anthracycline-based chemotherapy [5]. In this trial, cardiac dysfunction was observed in 
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27% of the women who received an anthracycline, cyclophosphamide, and trastuzumab; 
8% of the women who received an anthracycline and cyclophosphamide alone; 13% of 
the women who received paclitaxel and trastuzumab; and only 1% of the women who 
received paclitaxel alone. Among these women, the incidence of cardiac dysfunction of 
New York Heart Association class III or IV was 16% among women who were treated with 
an anthracycline, cyclophosphamide, and trastuzumab; 3% among women who received 
an anthracycline and cyclophosphamide alone; 2% among women who received paclitaxel 
and trastuzumab; and 1% among those who were treated with paclitaxel alone (Table 2). 
Given a high risk of symptomatic heart failure with the concomitant use of trastuzumab 
with anthracycline, in all adjuvant breast cancer trials, trastuzumab was only used after 
anthracyclines or with anthracycline-free chemotherapy. A Cochrane review assessed effi-
cacy and safety of trastuzumab in seven trials, involving 1497 women with advanced breast 
cancer [10]. Trastuzumab increased the risk of congestive heart failure (CHF) (RR 3.49, 90% 
CI 1.88–6.47, p-value = 0.0009) and left ventricular ejection fraction (LVEF) decline (RR 2.65, 
90% CI 1.48–4.74, p-value = 0.006).
In the major adjuvant trastuzumab clinical trials, the rates of symptomatic CHF varied 
from 0.6 to 4.1%, whereas the rates of symptomatic or minimally symptomatic reduction in 
LVEF ranged from 4 to 34% (Table 3). The Herceptin Adjuvant (HERA) trial compared 1 or 
2 years of trastuzumab given once every 3 weeks with observation in women with HER2-posi-
tive breast cancer. The incidence of trastuzumab discontinuation due to cardiac disorders was 
4.3% [8]. The incidence of cardiac end points was higher in the trastuzumab group compared 
with observation: severe CHF, 0.60% compared with 0.06%; symptomatic CHF, 2.15% com-
pared with 0.12%; and confirmed significant LVEF drops, 3.04% compared with 0.53%. Most 
women with cardiac dysfunction recovered in fewer than 6 months.
The National Surgical Adjuvant Breast and Bowel Project trial B-31 compared doxorubicin 
and cyclophosphamide (AC) followed by paclitaxel with AC followed by paclitaxel plus 
52 weeks of trastuzumab beginning concurrently with paclitaxel in women with node-
positive, HER2-positive breast cancer [27]. Among women with normal post-AC LVEF 
Class New York association functional classification Canadian Cardiovascular Society 
functional classification
I Patients with cardiac disease but without resulting limitations of 
physical activity
Ordinary physical activity, such as 
walking and climbing stairs, does not 
cause angina
II Patients with cardiac disease resulting in slight limitation of physical 
activity
Slight limitation of ordinary activity
III Patients with cardiac disease resulting in marked limitation of 
physical activity
Marked limitation of ordinary 
physical activity
IV Patients with cardiac disease resulting in inability to carry on any 
physical activity without discomfort
Inability to carry on any physical 
activity without discomfort
Table 2. New York association and Canadian Cardiovascular Society functional classifications.
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Trial N Design Definition of severe 
cardiotoxicity
Frequency of monitoring Asymptomatic 
drop in LVEF (≥10% 
points to <55%)
Severe CHF/cardiac 
events (NYHA class 
III/IV CHF or death)
Discontinued 
for cardiac 
reasons
FinHer12, 29 232 V or T + H versus 
V or Ta ≥FEC × 3
Myocardial infarction; HF; 
or LVEF decrease >15 points
Echo or MUGA before 
chemotherapy, after FEC, 
and 12 and 36 months after 
chemotherapy
3.5 versus 8.6% 0.9 versus 1.7% n/a
NSABP 
B-3127, 14
2030 AC + TH + H 
versus AC + T
Grade III/IV HF or cardiac 
death; or LVEF decrease >15 
pointsb
MUGA 3 weeks, 6, and 
9 months after end of initial 
AC, and 3 months after last 
trastuzumab dose
34 versus 17% 4.1 versus 0.8% 19%c
BCIRG 0066 3222 AC + T versus 
AC + TH + H 
versus TCaHd
Grade III/IV HF; cardiac 
death; grade 3–4 
arrhythmias; grade 3–4 
ischemia/infarction; or LVEF 
decrease >10 pointsb
After AC, after second 
dose of docetaxel, at end of 
chemotherapy, and 3, 12, and 
36 months after randomization
11 versus 19% 
versus 9%
0.7 versus 2.0% 
versus 0.4%
n/a
NCCTG 
N983128, 14
3505 AC + TH + H 
versus AC + T + H 
versus AC + T
Grade III/IV HF or cardiac 
death; or LVEF decrease >15 
pointsb
MUGA or echo at entry, after 
AC, and 6, 9, 18, and 21 months 
after entry
5.8–10.4 versus 
4.0–7.8% versus 
4.0–5.1%
3.3 versus 2.8% 
versus 0.3%
n/ab
HERA8, 13 5090 Adj chemoce ≥H 
versus Adj chemo 
alone
Severe HF; symptomatic HF; 
or LVEF decrease >10 points
LVEF (echo or MUGA) at 
baseline, 3, 6, 12, 18, 24, 30, 36, 
and 60 months
7.1 versus 2.2% 0.6 versus 0.06% 4.3%
A: anthracycline; C: cyclophosphamide; T: taxane; H: trastuzumab; Ca: carboplatin; V: vinorelbine; F: 5-flourouracil; E: epirubicin; n/a: information not available; HF: heart 
failure; LV0EF: left ventricular heart failure; MUGA: multi-gated acquisition scan.
a No prior anthracycline before H exposure; H exposure limited to 9 weeks.
b Measured from baseline.
c 6.7% did not receive H after A due to unacceptable drops in LVEF.
d Included a nonanthracycline arm.
e 96% of chemotherapy was A containing.
Table 3. Rates of asymptomatic and symptomatic cardiac dysfunction in various adjuvant trastuzumab phase 3 clinical trials.
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who began post-AC treatment, 5 of 814 (0.006%) women in the control group developed a 
cardiac event compared with 31 of 850 (0.036%) women treated with trastuzumab. The dif-
ference in cumulative incidence at 3 years was 3.3% (4.1% for trastuzumab-treated women 
minus 0.8% for control patients; 95% CI 1.7–4.9%). Twenty-seven of the 31 patients in 
the trastuzumab arm have been followed for ≥6 months after diagnosis of a CE; 26 were 
asymptomatic at last assessment; and 18 remained on cardiac medication. Fourteen per-
cent of patients discontinued trastuzumab because of asymptomatic decreases in LVEF; 
4% discontinued trastuzumab because of symptomatic cardiotoxicity.
In the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial, women 
with HER2-positive operable breast cancer were randomly assigned to AC followed by either 
weekly paclitaxel (arm A); paclitaxel then trastuzumab (arm B); or paclitaxel plus trastu-
zumab then trastuzumab alone (arm C) [28]. There were 1944 women with satisfactory or 
no LVEF evaluation who proceeded to post-AC therapy. Cardiac events (CHF or cardiac 
death) were as followed: arm A, n = 3; arm B, n = 19; and arm C, n = 19 with 3-year cumula-
tive incidences of 0.3, 2.8, and 3.3%, respectively. Incidence of asymptomatic LVEF decreases 
requiring holding trastuzumab was 8–10%; LVEF recovered and trastuzumab were restarted 
in approximately 50%.
The Breast Cancer International Research Group randomly assigned 3222 women with 
HER2-positive early-stage breast cancer to receive doxorubicin and cyclophosphamide fol-
lowed by docetaxel every 3 weeks (AC-T), the same regimen plus 52 weeks of trastuzumab 
(AC-T plus trastuzumab), or docetaxel and carboplatin plus 52 weeks of trastuzumab 
(TCH) [6]. The incidence of congestive heart failure in the two trastuzumab-containing 
regimens was higher in the group receiving AC-T plus trastuzumab (2.0%) than in the AC-T 
group (0.7%) or the TCH group (0.4%); the incidence with AC-T plus trastuzumab as com-
pared with TCH was increased by a factor of five. In addition, a significant difference in 
sustained, subclinical loss of mean LVEF (defined as >10% relative loss), was observed in 
the group receiving AC-T plus trastuzumab, as compared with the TCH group (18.6 versus 
9.4%, p-value < 0.001), with a rate of 11.2% in the AC-T group. Of 194 of the 1042 patients 
(19%) who had a relative reduction in LVEF of more than 10% in the group receiving AC-T 
plus trastuzumab, the decrease persisted for at least 4 years after randomization in 33% of 
the women.
The FinHer investigators randomly assigned 1010 women to receive three cycles of docetaxel 
or vinorelbine, followed by three cycles of fluorouracil, epirubicin, and cyclophosphamide 
(FEC). The 232 women with HER2-positive cancer were further assigned to receive or not to 
receive nine weekly trastuzumab infusions [12]. The incidence of symptomatic heart failure 
among the HER2-positive women was 0.9% (one patient) with trastuzumab and 1.7% (two 
patients) without trastuzumab. The incidence of absolute declines in LVEF >20% points from 
baseline was 6.8% with trastuzumab and 10.5% without trastuzumab [12, 29].
The Cochrane review evaluated toxicity of trastuzumab in eight studies involving 11,991 
women with early-stage breast cancer [11]. Trastuzumab significantly increased the risk of 
CHF (RR 5.11; 90% CI 3.00–8.72, p-value < 0.00001) and LVEF (RR 1.83; 90% CI 1.36–2.47, 
p-value = 0.0008).
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3.2. Lapatinib and other HER2‐directed therapies
In the Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization trial (ALTTO), 
8381 women with HER2-positive early breast cancer were randomly assigned to 1 year of 
adjuvant therapy with trastuzumab, lapatinib, their sequence (T → L), or their combination 
(L + T). Overall, incidence of primary or secondary cardiac end points was low in all treatment 
arms; primary cardiac end points occurred in 0.25–0.97% of women. Three fatal cardiac events 
occurred in the T → L arm and one in each of the other treatment arms [17].
A comprehensive analysis of 49 clinical trials involving 3689 women treated with lapatinib 
reported a low rated of cardiac events [30]. For example, asymptomatic cardiac events were 
reported in 53 women (1.4%), and symptomatic grade III and IV systolic dysfunction was 
observed only in 7 women (0.2%) treated with lapatinib. Cardiac safety of lapatinib in combi-
nation with trastuzumab is reviewed in the section of dual HER2-directed therapy.
Cardiotoxicity of pertuzumab was usually reported with the trastuzumab combination, 
and no additive cardiotoxicity was reported with addition of pertuzumab to trastuzumab. 
In phase I–III trials of pertuzumab, cardiac dysfunction was seen in 4.5–14.5% of women 
with pertuzumab treatment and cardiac dysfunction was usually grade I and II [30]. 
Cardiac safety of pertuzumab is reviewed in more detail in the section of dual HER2-
directed therapy.
T-DM1 had a better safety profile compared to trastuzumab, and no significant cardio-
toxicity was observed with T-DM1 in heavily pre-treated women. In the EMILIA study, 
only in 1.7% of women in the T-DM1 group experienced reduction in LVEF and grade III 
LVEF reduction developed only in one woman (0.2%) in the T-DM1 group compared to 
the lapatinib plus capacitabine group [23]. In phase I-II trials with neratinib, no cardio-
toxicity was reported, whereas cardiotoxicity was seen between 0 and 5.3% with afatinib 
treatment [30].
3.3. Dual HER2‐directed therapy
Several trials have evaluated dual HER2-directed therapy using trastuzumab in combination 
with lapatinib or pertuzumab in the neoadjuvant setting and metastatic breast cancer. These 
trials reported the risk of heart failure with dual HER2-directed therapy [20, 26, 31–34]. 
A meta-analysis of randomized clinical trials compared the risk of cardiac adverse events 
with dual HER2-directed therapy to HER2 monotherapy and reported a comparable cardiac 
toxicity between combination and mono-HER2-directed therapies [35]. Overall incidence 
results for CHF in dual HER2-directed and monotherapy were 0.88% (95% CI 0.47–1.64%) 
and 1.49% (95% CI 0.98–2.23%). The incidence of LVEF decline was 3.1% (95% CI 2.2–4.4%) 
and 2.9% (95% CI 2.1–4.1%), respectively. When stratified by each treatment combination, the 
incidence of CHF was 0.96% (95% CI 0.40–2.31%) for the trastuzumab plus lapatinib combina-
tion and 0.80% (95% CI 0.33–1.93%) for the trastuzumab plus pertuzumab combination, while 
the LVEF decline was 3.2% (95% CI 1.8–5.7%) and 3.1% (95% CI 1.9–4.8%), respectively. The 
odd ratio of CHF between dual and monotherapy was 0.58 (95% CI 0.26–1.27, p-value = 0.17), 
while the odd ratio of LVEF decline was 0.88 (95% CI 0.53–1.48, p-value = 0.64). Among the 
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two trials in the metastatic setting [19, 31], there was no association between dual anti-HER2 
therapy and either CHF (OR: 0.85, 95% CI 0.31–2.37, p-value = 0.76) or LVEF decline (OR: 
1.11, 95% CI 0.24–5.02, p-value = 0.90). Among the four trials in the neoadjuvant setting, there 
was also no evidence of an association between dual anti-HER2 therapy and CHF (OR: 0.74, 
95% CI 0.02–29.54, p-value = 0.87) or LVEF decline (OR: 1.52, 95% CI 0.44–5.32, p-value = 0.51) 
[20, 32–34]. For CHF, the pooled ORs for the comparison trastuzumab plus lapatinib versus 
trastuzumab and trastuzumab plus lapatinib versus lapatinib were 0.33 (95% CI 0.08–1.41, 
p-value = 0.13), and 0.64 (95% CI 0.22–1.88, p-value = 0.42), respectively. For LVEF decline, 
the pooled ORs for the trastuzumab plus lapatinib versus trastuzumab, trastuzumab plus 
lapatinib versus lapatinib, and trastuzumab plus pertuzumab versus trastuzumab were 0.53 
(95% CI 0.07–3.98, p-value = 0.54), 2.27 (95% CI 0.69–7.49, p-value = 0.18), and 0.66 (95% CI 
0.36–1.23, p-value = 0.19), respectively. Another systematic review and meta-analysis com-
pared treatment outcomes for women who received single or combined anti-HER2 therapies 
[21]. Overall, no statistically significant difference in the risk of heart failure between dual 
anti-HER2 therapy and monotherapy was noted (RR, 0.79; 95% CI 0.23–2.68; p-value = 0.71). 
Likewise, no statistically significant difference in risk of left ventricular ejection fraction 
decline was noted single versus dual HER2-directed therapy (RR, 1.12; 95% CI 0.51–2.44; 
p-value = 0.77).
Overall, cardiac toxicity is more often noted with the regimens employing sequential anthra-
cycline and taxanes. Nonetheless, the majority of women who received the therapy displayed 
neither acute nor delayed cardiac toxicity [29]. The rates of cardiac dysfunction with the 
novel HER2-targeted therapies are significantly lower than the trastuzumab. Furthermore, 
the combination of anti-HER2 treatment does not increase the cardiac toxicity compared to 
trastuzumab alone. Longer-term follow-up is required to determine the full effect of adverse 
cardiac events.
4. Pathophysiology of cardiac dysfunction
Cardiac dysfunction is a potential short- or long-term complication of several anticancer 
therapies. Although the underlying pathophysiology of trastuzumab and other novel HER2-
directed therapy-induced cardiac toxicity is not fully understood, it is different from that 
of anthracycline-related or type I cardiac dysfunction and has been classified as type II car-
diac dysfunction [36]. Whereas anthracycline-associated or type I cardiac dysfunction is dose 
dependent, cumulative, and potentially irreversible and has been associated with structural 
myocardial abnormalities, such as vacuolization, myofibrillar disarray and drop-out, and 
myocyte necrosis, trastuzumab-related or type II cardiac dysfunction is not dose related, 
does not appear to occur in all individuals, is expressed in a broad range of severity, is not 
related to identifiable structural changes, and, more importantly, appears to be reversible 
(Table 4) [36, 37].
Trastuzumab-induced cardiac dysfunction is considered to be the result of attenuated HER2-
mediated signaling in the heart, culminating in decreased functionality of cardiac myocytes. HER 
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signaling plays an important role in modulating myocardial response to chemotherapy-induced 
injury and inhibition of the HER-2/erbB2 receptor worsens anthracycline-associated cardiotoxicity 
[38]. HER or ErbB receptors are family of transmembrane tyrosine kinase receptors that bind extra-
cellular ligands and regulate cell growth, differentiation, and survival [39]. HER2 appears to func-
tion as a compensatory mechanism acting against cardiac stress, such as anthracycline-induced 
cardiotoxicity. Subsequent administration of trastuzumab may then lead to an inhibition of this 
compensation, resulting in heart failure [40]. Trastuzumab induces down-regulation of HER2 
receptors which leads to apoptosis by disrupting downstream cytoprotective signaling pathways 
and by decreasing expression of Bcl-2 anti-apoptotic protein [41]. Discontinuation or trastuzumab 
withdrawal allows recovery of signaling pathway and reversal of LVEF decline, in contrast to the 
permanent myocyte dysfunction and damage caused by anthracyclines.
Trastuzumab-induced cardiotoxicity is demonstrated by inhibiting ErbB2 signaling in rat car-
diac myocytes with a suitable antibody. This process promotes intrinsic (mitochondrial) apop-
totic pathway that involves an increase in Bcl-XS/Bcl-XL ratio [42, 43]. Some studies showed that 
Type I cardiac dysfunction  
(myocardial damage)
Type II cardiac dysfunction 
(myocardial dysfunction)
Prototype drug • Doxorubicin • Trastuzumab
Natural history • typically permanent and irreversible
• recurrence in months or years may 
be related to sequential cardiac stress
• reversible with high likeli-
hood of recovery to baseline 
heart function in 2–4 months
Dose relationship • dose-dependent
• cumulative
• dose independent
Pathophysiology • oxidative stress/damage
• free radical formation
• blockade of HER2 signaling 
in myocardium
Electron microscopic findings • vacuoles
• myofibrillar disarray and dropout
• necrosis
• changes resolve over time
• no characteristic structural 
abnormalities
Noninvasive cardiac testing Findings • decreased ejection fraction
• global decrease in wall motion
• decreasedejection fraction
• global decrease in wall motion
Effect of rechallenge • high risk of progressive recurrent 
dysfunction
• may result in intractable heart failure 
and death
• may be safe and appropriate 
for some individuals
Effect of late sequential stress • High likelihood of sequential stress-
related cardiac dysfunction
• Low likelihood of sequen-
tial stress-related cardiac 
dysfunction
Table 4. Cancer treatment-related cardiac dysfunction.
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trastuzumab down-regulates neuregulin-1 (NRG-1), which is released in endocardium and acti-
vates MAPK and the PI3K/AKT cell survival pathways as well as focal adhesion kinases (FAK) 
in cardiomyocytes which are all important for the function and structure of cardiomyocytes [44].
In general, women who develop cardiotoxicity while receiving trastuzumab therapy improve 
upon withdrawal of the drug. Evidence suggests that reintroducing trastuzumab may be 
appropriate for some individuals who previously have experienced trastuzumab-related car-
diac dysfunction.
5. Risk factors
The following are the risk factors for trastuzumab-associated cardiotoxicity identified in the 
adjuvant clinical trials: prior treatment with anthracycline-based chemotherapy; a borderline 
low normal left ventricle ejection fraction; prior treatment with antihypertensive medication; 
older age; and a body mass index >25 kg/m2 [7, 29]. In the HERA trial, the women who had 
a cardiac end point received a significantly higher dose of epirubicin and doxorubicin than 
the women without [8]. Furthermore, women with a screening LVEF of <60% had a signifi-
cantly higher incidence of cardiac end points than women with a higher screening LVEF ≥60% 
(6.90% versus 2.72%; 95% CI 1.33–7.02%). Women with a risk factor of hypertension, current 
smoker, diabetes, hypothyroidism, or age ≥60 showed a trend to a higher incidence of cardiac 
end points that was not significant.
In NSABP B-31 trial, CHFs were more frequent in older women and women with marginal 
post-AC LVEF [27]. LVEF, assessed either at baseline or after AC, was strongly associated with 
subsequent CHF (P < 0.0001), and age at entry was also predictive (P = 0.03). Hypertension was 
marginally significant (P = 0.07). In a multivariate analysis, age and post-AC LVEF remained 
statistically significant.
The NSABP B31 data about risk factors for a cardiac event are supported by NCCTG N9831 
trial [28, 29]. For example, women ≥60 years had a risk of 6.6%, women aged 50–59 years had 
a 2.8% risk, and women <50 years had a 2.1% risk (P = 0.003). Previous or current use of anti-
hypertensive agents increased the risk to 6.0% (P = 0.005). Baseline LVEF above the lower limit 
of normal but <55% increased the risk to 5.6% (P = 0.033). BMI (P = 0.161) and post-AC LVEF 
level (P = 0.134) were not significantly correlated with LV dysfunction.
6. Monitoring
Women treated with adjuvant trastuzumab and other HER2-directed treatment require 
appropriate monitoring of LV function. LVEF measurement, obtained by echocardiogram or 
radionuclide ventriculography (multiple-gated acquisition [MUGA] scans), is currently the 
generally accepted diagnostic tool to detect cardiotoxicity of antineoplastic agents. It is impor-
tant to note that the LVEF reflects the functional status of the left ventricle, and until func-
tional impairment occurs, myocardial injury will not be detected by LVEF measurement [40].
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With about a decade of follow-up involving women treated in the adjuvant setting with 
trastuzumab-containing regimens, the optimal surveillance for trastuzumab-related cardio-
toxicity is not known. The available evidence does not definitively support a specific schedule 
of screening or demonstrates improved outcomes for the screened patients [45]. In the adju-
vant setting, a baseline evaluation for cardiac function is performed with a repeat testing at 
3, 6, 9, and 12 months [46]. In metastatic disease, HER2-directed therapy is continued until 
disease progression. LVEF is typically monitored at baseline, during the first 3–12 months 
of therapy and then as clinically indicated such as the presence of symptoms suggestive of 
cardiac dysfunction.
The optimal cardiac monitoring of women who are receiving novel HER2-directed therapy 
is not known. The United States Food and Drug Administration (US FDA) prescribing infor-
mation recommends that all women who are treated with pertuzumab or lapatinib or TDM1 
have LVEF assessed at the treatment initiation and subsequently at regular intervals (i.e., 
every 3 months in the metastatic setting and every 6 weeks in the neoadjuvant setting) [47–49]. 
Given that cardiac dysfunction rates of novel HER2-targeted therapies are not high and the 
combination of anti-HER2 treatment does not increase the cardiac toxicity compared with 
trastuzumab, periodic monitoring of cardiac function in otherwise asymptomatic women 
with metastatic breast cancer may not be cost effective.
The early detection of injured myocardial cells is required more sensitive diagnostic tools than the 
use of conventional methods for LVEF measurement. For example, several small studies have eval-
uated tissue Doppler and strain rate imaging to detect early subclinical changes in cardiac function 
during and after cancer treatment that preceded a decrease in LVEF [50, 51]. Contrast ECG and 
real-time 3D ECG are under investigation that may allow improvement in the accuracy of calcu-
lating LVEF. In addition, early identification of women at high risk of cardiotoxicity by cardiac 
biomarkers, in particular, troponin can be more effective for targeted preventive strategies [50].
7. Treatment of cardiac dysfunction
A multidisciplinary approach for the management of treatment-related cardiotoxicity is 
important for optimal outcomes. Cardio-oncology is a new interdisciplinary field of growing 
interest focusing on management and prevention of therapy-related cardiac dysfunction in 
cancer patients [52].
Management of trastuzumab and other HER2-directed treatment-related cardiac dysfunction has 
two key components: withdrawal of trastuzumab and other HER2-directed therapy and treatment 
of underlying cardiac dysfunction. Although in the adjuvant clinical trials, various “stopping and 
restarting” criteria were used for asymptomatic declined in LVEF, the optimal withdrawal and 
continuation schedule for asymptomatic decline in LVEF in general population are not known.
The NSABP B-31 and the NCCTG N9831 trials used the following dosing guidelines.
• If there is 16% or greater decline in LVEF from the baseline value or 10–15% declined in 
ejection fraction to below the lower limit of normal of LVEF, trastuzumab is withheld for 
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4 weeks and reassessment of LVEF at week four. Discontinue trastuzumab if at 4 weeks 
LVEF remains below that levels.
• Discontinue trastuzumab if a person develop symptomatic heart failure during treatment 
with trastuzumb, it is discontinued.
Symptomatic heart failure is defined as the presence of:
• dyspnea, pedal edema, and orthopnea;
• the presence of sinus tachycardia, raised jugular venous pressure, tachypnea, crackles, and 
S3 heart sound;
• radiographic evidence of pulmonary congestion or edema.
One of the algorithms for monitoring of cardiac function for women on adjuvant trastuzumab 
is described in Figure 1.
Unlike early-stage breast cancer, the dosing criteria for women with metastatic breast cancer 
are not well defined. In clinical practice, left ventricle function monitoring is infrequently 
performed in otherwise asymptomatic women with metastatic breast cancer.
Angiotensin-converting enzyme (ACE) inhibitors and beta-blockers have been proven to delay 
or reverse LV dilation and improve ejection fraction [53–55]. All women with symptomatic heart 
failure should be treated with an ACE inhibitor in combination with a beta-blocker unless a spe-
cific contraindication exists. HER2-directed therapy should be permanently discontinued in such 
women. ACE inhibitors in combination with a beta-blocker should be used in all asymptomatic 
Figure 1. Algorithm for stop and restarting trastuzumab based on LVEF assessments.
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women with LV dysfunction and an ejection fraction below 40% unless a specific contraindica-
tion exists. Women with LVEF >40% may also get benefit from pharmacological intervention [56, 
57]. The optimal duration of therapy is not known and is determined by several factors such as 
the degree of lv dysfunction, recovery of LV function, patient symptoms, and preference.
7.1. Lapatinib
The US FDA prescribing information recommends discontinuation of lapatinib for a decline 
in the LVEF to <50%, for those whose LVEF drops below the institution's lower limit of normal 
and for any women who develop symptomatic heart failure during therapy [49]. Dose reduc-
tion is recommended if the LVEF recovers to normal after a minimum of 2 weeks in otherwise 
asymptomatic patients.
7.2. Pertuzumab
The US FDA prescribing information recommends to withhold both pertuzumab and trastu-
zumab if LVEF is <45% or is 45–49% with a ≥10% absolute decrease below the baseline value 
and suggests discontinuing both pertuzumab and trastuzumab if the LVEF has not improved 
or has declined further on repeat assessment in 3 weeks [47].
7.3. Ado‐trastuzumab emtansine (T‐DM1)
For women who are treated with T-DM1, at least temporary discontinuation of therapy is 
recommended if the LVEF falls to <40% or is 40–45% with a ≥10% absolute decrease below the 
pretreatment value [48].
8. Preventive strategies
The presence of underlying cardiovascular risk factors can increase the risk of treat-
ment-related cardiac dysfunction. Cardiovascular risk reduction with appropriate control 
of blood pressure, cholesterol, and blood glucose, as well as positive health-promoting 
behavior, including healthy diet, smoking cessation, regular exercise, and weight control, 
is recommended for women with breast cancer to reduce the risk of treatment-related car-
diotoxicity [50, 58, 59]. Several strategies have been developed to mitigate the risk of both 
symptomatic and asymptomatic cardiac dysfunction related to HER2-directed therapy. 
These interventions include periodic cardiac function monitoring, use of a non-anthra-
cycline-based chemotherapy, stopping and restarting HER2-directed therapy, and early 
detection of cadiotoxicity by biomarkers, followed by prophylactic intervention in selected 
high-risk patients.
HER2-directed therapy should be avoided in women with a significant cardiovascular his-
tory such as recent myocardial infarction, CHF, unstable angina, significant arrhythmias, 
uncontrolled hypertension, LV hypertrophy, or significant valvular heart disease. The cardiac 
toxicity data from the adjuvant trastuzmab trials suggest three approaches which have been 
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associated with a reduced risk of cardiac toxicity. The first approach employed by the HERA 
investigators, which is the sequential use of trastuzumab after completion of adjuvant chemo-
therapy. This approach resulted in very low rates of cardiac toxic effects, despite the fact that 
94% of women received an anthracycline-based regimen [29]. However, the direct compari-
son of concurrent versus sequential administration of trastuzumab in the N9831 trial suggests 
that even though the sequential approach is effective, concurrent administration provides 
greater benefit with minimal increased risk for cardiac toxicity [3, 29].
A second approach was employed in FinHer trial which used 9-week duration of adjuvant 
trastuzumab and showed a very low rate of cardiac dysfunction [29]. However, the non-infe-
riority of shorter duration of trastuzumab is not confirmed in a randomized clinical trial. 
In the Protocol for Herceptin as Adjuvant therapy with Reduced Exposure (PHARE) trial, 
3380 women were randomly assigned 6 versus 12 months of trastuzumab [60]. The overall 
incidences of CHF were 0.65 and 0.53% in the 12 and 6 months arms, respectively (p > 0.05). 
Cardiac dysfunction occurred in 5.9 and 3.4% of women in the 12 and 6 months arms, respec-
tively (p = 0.001) [61]. However, with a median follow-up of 42.5 months, treatment for 
6 months resulted in a shorter 2-year DFS rate compared with 12 months of therapy (91 ver-
sus 94%, respectively; HR 1.28, 95% CI 1.05–1.56). In addition, treatment for 6 months resulted 
inferior overall survival (93 versus 66 events; HR 1.46, 95% CI 1.06–2.01) and more frequent 
distant recurrences (HR 1.33, 95% CI 1.04–1.71). Hence, the approach of 6 months or shorter 
duration of adjuvant trastuzumab is not recommended.
The third approach is the use of a non-anthracycline-based chemotherapy regimen such 
as docetaxel and carboplatin plus 1 year of trastuzumab (TCH → H) that was employed in 
the BCIRG 006 trial. The rate of symptomatic congestive heart failure was only 0.4% with 
TCH → H compared with a rate of 2.0% with AC → TH → H [6]. A non-anthracycline-based 
regimen also eliminates the risk of cardiac dysfunction from anthracycline that may preclude 
the use of adjuvant trastuzumab. The risk for cardiotoxicity with an anthracycline-based regi-
men can be reduced by identifying women who are at increased risk for cardiac dysfunction 
and avoiding such regimen in these women.
The primary prevention using a beta-blocker or an ACE inhibitor has been employed as an 
approach to reduce cancer therapy-related cardiac toxicity [62–64]. The results of the PRADA 
(prevention of cardiac dysfunction during adjuvant breast cancer therapy) trial have shown 
that candesartan—but not metoprolol—concomitantly administrated with adjuvant che-
motherapy including epirubicin, with or without trastuzumab, can protect against early 
decline in LVEF, assessed with cardiac magnetic resonance [62]. MANTICORE 101-Breast 
(Multidisciplinary Approach to Novel Therapies in Cardiology-Oncology Research) is a 
randomized trial that evaluated if conventional heart failure pharmacotherapy can prevent 
trastuzumab-mediated left ventricular remodeling, measured with cardiac MRI. The study 
randomized 99 women with HER2-positve breast cancer in a 1:1:1 ratio to an ACE inhibitor 
(perindopril), beta-blocker (bisoprolol), or placebo [63, 64]. The study failed to achieve its pri-
mary end point and neither a beta-blocker nor an ACE inhibitor, used as prophylaxis against 
trastuzumab's adverse cardiac effects, and successfully prevented left ventricle remodeling. 
The post-treatment LVEF for placebo patients was significantly but not clinically worse than 
in either of the experimental arms—56% versus 59% for perindopril and 61% for bisoprolol 
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(down from 61, 62 and 62%, respectively). Although prophylactic beta-blocker or ACE inhibi-
tor is currently not recommended in women with normal baseline LVEF, it may consider in 
woman at high risk of cardiac dysfunction.
9. Conclusions
The HER2-directed therapy including monoclonal antibodies such as trastuzumab, small 
molecule inhibitors, and antibody-drug conjugates has revolutionized the management of 
women with early and advanced HER2-positive breast cancer. Left ventricle dysfunction is 
a known adverse effect of trastuzumab and other HER-2 directed therapy. In most cases, it 
is mild and reversible; however, symptomatic heart failure is not a rare complication. The 
optimal approach to reduce treatment-related LV dysfunction, the best method for its early 
detection, and the optimal regimen to prevent it remain unknown. Appropriate patient selec-
tion for HER2-directed therapy and cardiac monitoring is essential to prevent and manage 
potential cardiac adverse events. A monitoring schedule that assesses baseline and on-treat-
ment cardiac function but potentially reduces the overall number of assessments is suggested 
for women on HER2-directed therapy. Intervention strategies with cardiovascular medication 
such as treatment with ACE inhibitor and beta-blockers and cardiovascular risk reduction to 
improve cardiac status before, during and after treatment, are important to reduce incidence 
of heart failure. Simplified rules for starting, interrupting and discontinuing trastuzumab are 
important for the management of LVEF reduction in women on HER2-directed therapy. We 
recommend a multidisciplinary approach for the management and prevention of treatment-
related cardiac dysfunction for the optimal outcomes.
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